Seroquel on Glucose Metabolism

AstraZeneca572 enrolled

Overview

The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

572

Conditions

Schizophrenia

Interventions

Seroquel (quetiapine)DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * In- or outpatients with schizophrenia, 18-65 years old, requiring a change in treatment due to insufficient efficacy or tolerability and giving signed informed consent. Exclusion Criteria: * Known diabetes mellitus, high HbA1c, fasting plasma glucose and/or high 2h glucose-OGTT. * Previous use of atypicals (3 months) or other medications that might influence glucose metabolism * Contraindications or non-responsiveness for any of the treatments or other safety issues * Expected non-compliance to treatment and/or study procedures

Locations (70)

Outcomes

Primary Outcomes

To analyze the safety/tolerability profile of quetiapine on glucose metabolism in schizophrenic patients

Secondary Outcomes

Glucose metabolism, blood lipid levels and weight

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Burgas, Bulgaria

Research Site

Rousse, Bulgaria

Research Site

Sofia, Bulgaria

Research Site

Sofia- Novi Iskar, Bulgaria

Research Site

Varna, Bulgaria

Research Site

Dobjany, Czechia

Research Site

Dob¿any U Plzn¿, Czechia

Research Site

Havlí¿k¿v Brod, Czechia

Research Site

Kladno, Czechia

Research Site

Miro¿ov, Czechia

...and 60 more locations